Meeting Banner
Abstract #1758

Liver proton density fat fraction as a trial endpoint in an international multi-site phase-II trial in patients with type 2 diabetes mellitus following treatment with duodenal mucosal resurfacing

Naomi S Sakai1, Alan Bainbridge2, David Maggs3, Margaret Hall-Craggs1, Rachel Batterham4,5, Stuart Taylor1, and Manil Chouhan1

1UCL Centre for Medical Imaging, University College London, London, United Kingdom, 2Department of Medical Physics, University College London Hospitals, London, United Kingdom, 3Fractyl Laboratories Inc., Lexington, MA, United States, 4Centre for Obesity Research, University College London, London, United Kingdom, 5National Institute of Health Research, UCLH Biomedical Research Centre, London, United Kingdom

Vendor-certified proton density fat fraction (PDFF) sequences are commercially available across multiple scanner systems and represent a robust method for quantification of liver fat and liver T2* mapping. Type 2 diabetes mellitus (T2DM) is associated with non-alcoholic fatty liver disease and dysregulation of iron homeostasis. Duodenal mucosal resurfacing (DMR) is a novel treatment for patients with T2DM who have poor glycaemic control. We describe our technique for quality assurance across multiple sites using custom fat-water phantoms and report preliminary liver PDFF and liver iron concentration results from a cross-site, multi-vendor study in patients at baseline and 12 weeks after DMR.

This abstract and the presentation materials are available to members only; a login is required.

Join Here